Lumos Pharma (NASDAQ:LUMO – Get Free Report) had its price objective cut by research analysts at Oppenheimer from $17.00 to $16.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s target price indicates a potential upside of 451.72% from the stock’s previous close. LUMO […]
Lumos Pharma (NASDAQ:LUMO – Free Report) had its target price cut by Oppenheimer from $18.00 to $17.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have an outperform rating on the stock. LUMO has been the subject of a number of other research reports. HC Wainwright reiterated a buy rating […]
K2 Principal Fund L.P. reduced its position in Lumos Pharma, Inc. (NASDAQ:LUMO – Get Rating) by 71.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,836 shares of the company’s stock after selling 40,030 shares during the quarter. K2 Principal Fund L.P.’s holdings […]
Lumos Pharma, Inc. (NASDAQ:LUMO – Get Rating) – Equities research analysts at HC Wainwright upped their Q2 2023 EPS estimates for shares of Lumos Pharma in a research report issued on Thursday, May 4th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($0.99) per share for the quarter, up […]